To evaluate the efficacy and safety of weight loss (WL) plus aromatase inhibitor (AI) therapy in severely obese men with hypogonadotropic hypogonadism (HHG). The gene discussed is CYP19A1; the disease is hypogonadotropic hypogonadism.